Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $27.55 Analyst target: $77.88 Upside: 182.69%
Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders, addressing significant unmet medical needs in the field of genetic medicine. The company boasts a promising and proprietary pipeline, showcasing its commitment to harnessing cutting-edge technologies for transformative treatment solutions. With a seasoned leadership team guiding its strategic direction, Neurogene is poised to make substantial contributions to the advancement of genetic therapies, ultimately enhancing the quality of life for patients and their families impacted by these challenging conditions. As Neurogene progresses through critical clinical development phases, it stands as a key player in the evolving landscape of genetic therapeutics.
See the full interactive analysis & chart →Informational only — not investment advice.